With these results, in 2012, the FDA approved the use of ivacaftor for the treatment of CF in those patients over 6 years of age who present some of the following opening or gating mutations (class III): G551D, G1244E, G1349D, G178R, S1251N, S1255P, S549R, and S549N in one of the alleles of the CFTR gene. Here, CFTR is linked to cystic fibrosis.